Clinical trial
A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
NCT03753087 is registered in ClinicalTrials.gov with National Medical Research Center for Cardiology, Ministry of Health of Russian Federation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 16, 2019
- Completion date
- January 10, 2022
- Enrollment
- 70 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.